Given its well-documented worse clinical outcomes and unique biological characteristics [22,23,24,25,26,27,28], TP53 Mut AML is now regarded as a distinct diagnostic entity separate from other subtypes of AML [4]. The gene discussed is TP53; the disease is acute myeloid leukemia.